Therefore, to explore the molecular mechanism by which HGF reduces sensitivity to gefitinib in lung cancer harboring wild-type EGFR, we examined the phosphorylation status of MET, EGFR, ErbB3, and the downstream signaling pathways by western blotting. This evidence concerns the gene EGFR and lung carcinoma.